In patients with RAS wild-type metastatic colorectal cancer (mCRC). an anti-epidermal growth factor receptor (EGFR) monoclonal antibody plus chemotherapy is a standard option for treatment in the first-line setting. Patients who progress while on treatment with anti-EGFR-based therapy can be resistant to further anti-EGFR treatment. but evidence suggests that the anti-EGFR-resistant c... https://yeswellneses.shop/product-category/prenatal/